10 research outputs found
A nationwide pilot study on breast cancer screening in Peru
"Introduction: A high prevalence of advanced breast cancer (BC) is a common scenario in
Latin America. In Peru, the frequency of BC at Stages III/IV is ≈50% despite implementation of a programme for breast cancer screening (BCS) along the country. We carried out
a study to assess the feasibility and develop an instrument to evaluate the knowledge,
barriers and perception about BCS in a nationwide pilot study in Peru among candidates
for BCS.
Methods: We conducted a systematic review of 2,558 reports indexed in PubMed, Scopus, Web of Science, Medline-Ovid and EMBASE, regarding to our study theme. In total,
111 were selected and a 51-items survey was developed (eight items about sociodemographic characteristics). Patients were recruited in public hospitals or private clinics, in
rural and urban areas of nine departments of Peru.
Results: We surveyed 488 women from: Lima (150), Cajamarca (93), Ica (59), Arequipa
(56), Loreto (48), Ancash (38), Junín (15), Puerto Maldonado (15) and Huancavelica (14);
27.9% of them were from rural areas. The mean of age was 53.3 years (standard deviation ± 9.1). Regarding education level, 29.8% had primary, 33.2% secondary and 37.0%
higher education. In total, 28.7% of women did not know the term ‘mammogram’ and
47.1% reported never receiving a BCS (36.9% from urban and 73.5% from rural population). In women that underwent BCS, only 67% knew it is for healthy women. In total,
54.1% of patients had low levels of knowledge about risk factors for BC (i.e. 87.5% of
women respond that injuries in the breast produce cancer). Cultural, economic and geographic barriers were significantly associated with having a mammogram where 56.9% of participants considered a cost ≤ 7 USD as appropriate. Mammogram was perceived as too painful for 54.9% of women. In addition, women
with a self-perception of low-risk for BC and a fatalistic perception of cancer were less likely to have a BCS.
Conclusion: We found that it is feasible to conduct a large-scale study in Peru. The results of this pilot study highlight an urgent need of
extensive education and awareness about BCS in Peru.
Efficacy of Neoadjuvant Carboplatin plus Docetaxel in Triple-Negative Breast Cancer: Combined Analysis of Two Cohorts
Recent studies demonstrate that addition of neoadjuvant (NA) carboplatin (Cb) to anthracycline/taxane chemotherapy improves pathological complete response (pCR) in triple negative breast cancer (TNBC). Effectiveness of anthracycline-free, platinum combinations in TNBC is not well known. Here we report efficacy of NA carboplatin + docetaxel (CbD) in TNBC
Westchester: The American Suburb
Today, more than half of Americans live in suburbs. A far cry from the “crabgrass frontier” of modest bedroom communities built for urban strivers, today’s sprawling, self-contained suburbs define our cultural landscape.
This fascinating book chronicles—in word and images—the history, development, and character of suburban America with an illuminating account of one of its signature places: Westchester, New York.
Designed as a companion to a major exhibition at The Hudson River Museum, the book brings together original essays by leading historians and other experts, and a rich selection of photographs, paintings, maps, ephemera, and other images that track more than century of growth, development, and change.
The essays explore key themes that run through Westchester’s legacy: the new transportation grids that make all suburbs possible, the suburban house as a new focal point for family life, the creation of a new domesticity, consumerism and community, architecture and nature. Also covered is the representation of suburban life in film, literature, art, photography, and the media.
From Washington Irving’s Sunnyside home built in 1830 to the virtual New Rochelle home of The Dick Van Dyke Show’s Rob and Laura Petrie, Westchester has been the iconic American suburb—loved and hated, desired and abandoned. Like the exhibition whose name it shares, this book is not just a testimony to a time gone by—but a vivid and provocative encounter with the porches, patios, and parkways that define the American dream
Current Scenario of Clinical Cancer Research in Latin America and the Caribbean
In Latin America and the Caribbean (LAC), progress has been made in some national and regional cancer control initiatives, which have proved useful in reducing diagnostic and treatment initiation delays. However, there are still significant gaps, including a lack of oncology clinical trials. In this article, we will introduce the current status of the region’s clinical research in cancer, with a special focus on academic cancer research groups and investigator-initiated research (IIR) initiatives. Investigators in LAC have strived to improve cancer research despite drawbacks and difficulties in funding, regulatory timelines, and a skilled workforce. Progress has been observed in the representation of this region in clinical trial development and conduct, as well as in scientific productivity. However, most oncology trials in the region have been sponsored by pharmaceutical companies, highlighting the need for increased funding from governments and private foundations. Improvements in obtaining and/or strengthening the LAC cancer research group’s financing will provide opportunities to address cancer therapies and management shortcomings specific to the region. Furthermore, by including this large, ethnic, and genetically diverse population in the world’s research agenda, one may bridge the gap in knowledge regarding the applicability of results of clinical trials now mainly conducted in populations from the Northern Hemisphere
Gender and outcomes in non-small cell lung cancer : an old prognostic variable comes back for targeted therapy and immunotherapy?
In silico evaluation of DNA Damage Inducible Transcript 4 gene (DDIT4) as prognostic biomarker in several malignancies
Efficacy of Neoadjuvant Carboplatin plus Docetaxel in Triple-Negative Breast Cancer: Combined Analysis of Two Cohorts
PURPOSE: Recent studies demonstrate that addition of neoadjuvant (NA) carboplatin (Cb) to anthracycline/taxane chemotherapy improves pathological complete response (pCR) in triple negative breast cancer (TNBC). Effectiveness of anthracycline-free, platinum combinations in TNBC is not well known. Here we report efficacy of NA carboplatin + docetaxel (CbD) in TNBC. PATIENTS AND METHODS: The study population includes 190 patients with stage I-III TNBC treated uniformly on two independent prospective cohorts. All patients were prescribed NA chemotherapy regimen of Cb (AUC 6) + D (75mg/m2) given every 21 days × 6 cycles. Pathological complete response (pCR: no evidence of invasive tumor in the breast and axilla) and Residual Cancer Burden (RCB) were evaluated. RESULTS: Among 190 patients, median tumor size was 35mm, 52% Lymph Node positive and 16% had germline BRCA1/2 mutation. The overall pCR and RCB 0+1 rates were 55% and 68%, respectively. pCR in patients with BRCA associated and wild-type TNBC were 59% and 56%, respectively (p=0.83). On multivariable analysis stage III disease was the only factor associated with a lower likelihood of achieving a pCR. 21% and 7% of patients, respectively, experienced at least one grade 3 or 4 adverse event. CONCLUSION: The CbD regimen was well tolerated and yielded high pCR rates in both BRCA associated and wildtype TNBC. These results are comparable to pCR achieved with addition of Cb to anthracycline-taxane chemotherapy. Our study adds to the existing data on the efficacy of platinum agents in TNBC and supports further exploration of the CbD regimen in randomized studies